• Safe Pro Group recently completed a 10-day U.S. Army exercise which was focused on next generation command and control, as well as emerging battlefield technologies.
• Throughout the exercise, Safe Pro trained soldiers on how small unmanned aircraft systems (“sUAS”) can be used together with Safe Pro’s AI-powered threat detection and mapping solutions.
• Safe Pro also announced that it will host an Innovation Day on August 25, 2026, which will feature live drone operations that highlight how American AI is used in the field.

Safe Pro Group (NASDAQ: SPAI), a company delivering advanced AI-powered security and defense solutions, recently completed its participation in the U.S. Army Project Convergence Capstone 6 (“PC-C6”) exercise (https://ibn.fm/Sq6nB).

The exercise was a future warfare experiment conducted by the Army and premier allied nations focused on emerging battlefield technologies including next generation command and control. It has the goal of evaluating new technologies and generating operational feedback that helps guide the Army’s modernization efforts in the future.

During the 10-day exercise, which took place at the National Training Center in California, Safe Pro trained soldiers on how small unmanned aircraft systems (“sUAS”) are able to be used together with Safe Pro’s patented AI-powered threat detection and mapping solutions operating on the edge.

Safe Pro’s backpack-sized Navigation Observation & Detection Engine-X (“NODE-X”) and OnSight software were also showcased in multiple missions in front of not only Army command and technical staff, but also a variety of distinguished visitors evaluating emerging technologies.

During the exercise, soldiers used NODE in realistic combat training conditions to analyze drone imagery and create detailed maps of threats like landmines and cluster munitions, while also rapidly sharing data across Army planning platforms to support better operational decision-making.

Speaking about Safe Pro’s participation in the exercise, Safe Pro Group CEO and Chairman, Dan Erdberg, said “We are thankful for the opportunity to work with soldiers and successfully complete the rigorous PC-C6 exercise. At this invite-only event, our teams were able to showcase our unique threat detection and mapping capabilities to the Army, providing further validation of the capability we can provide to ground forces on the modern battlefield and supporting the Army’s broader modernization priorities.”

In addition to successfully participating in this exercise, Safe Pro Group recently announced that it would be hosting an Innovation Day (https://ibn.fm/dkc8s). Taking place on August 25, 2026, in Aventura, Florida, this event will feature live drone operations that highlight how American AI is used in the field. During Innovation Day, Safe Pro’s leadership team will also provide corporate updates, an overview of its expanding AI threat mapping solution portfolio and highlight developments in its government contracting pipeline.

There will also be a live aerial demonstration of Safe Pro’s AI-powered real-time threat detection capabilities, including key elements of the Safe Pro Object Threat Detection (“SPOTD”) technology. Following the presentations, there will also be a live Q&A session.

In-person attendance at the event is limited to institutional investors and analysts, but portions of the event, along with supporting materials, will be made available live or through an archived replay on Safe Pro’s investor relations website at https://safeprogroup.com/investors.

About Safe Pro Group Inc. (NASDAQ: SPAI)

Safe Pro Group is a mission-driven tech company that develops and deploys AI-driven security and defense solutions to companies in the humanitarian, homeland security, defense, and law enforcement industries. The heart of Safe Pro’s mission is the patented computer vision technology that rapidly detects, identifies and maps small objects and threats in drone-based images and videos to enable more efficient and safer field operations. Safe Pro has the vision of leading the evolution of security and threat detection through AI innovation.

For more information, visit Safe Pro Group’s website at www.SafeProGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

• TechForce Robotics is expanding AI-powered automation across semiconductor manufacturing, industrial facilities, hospitality and healthcare.
• The company’s strategic alliance with JJ Enterprise is expanding alongside accelerating customer demand, including plans to evaluate up to 100,000 square feet of additional manufacturing capacity across Taiwan and the United States.
• These developments reinforce Nightfood Holdings’ strategy of building the physical automation technologies powering the next generation of AI.

Artificial intelligence has evolved far beyond software models and cloud computing. While companies such as AMD, NVIDIA and Broadcom have captured headlines with increasingly powerful AI chips, the next phase of the AI revolution is being built in factories, semiconductor fabrication plants, logistics hubs and industrial facilities. Every new AI data center, advanced chip manufacturing facility, and automated production line requires sophisticated robotics, precision engineering, and intelligent automation systems, creating a rapidly expanding investment opportunity that extends well beyond semiconductor designers (ibn.fm/jDgeG).

Nightfood Holdings (OTCQB: NGTF), operating under the name TechForce Robotics, is positioning itself within this industrial transformation by developing AI-driven automation solutions for hospitality, laboratory, pharmaceutical, and industrial applications. As AI infrastructure spending accelerates globally, the company is expanding its capabilities to address growing demand for the physical technologies that enable intelligent manufacturing and automated operations.

Industry estimates suggest roughly $1 trillion will be invested globally in semiconductor fabrication facilities through 2030, while more than $645 billion in private semiconductor investments have already been announced across the United States since 2020. The migration of Taiwan’s semiconductor supply chain into North America, supported by the CHIPS Act and expanding U.S.-Taiwan trade initiatives, is further driving demand for advanced manufacturing, automation and precision engineering. Each new semiconductor fabrication plant requires significant investment in robotics, automated material handling, precision engineering and intelligent production systems, creating opportunities throughout the broader AI infrastructure ecosystem.

TechForce Robotics is strategically aligning its business with these secular growth trends. The company’s strategic alliance with Taiwan-based Jiun Jiang Enterprise Co. Ltd. (“JJ Enterprise”) provides access to decades of expertise in semiconductor-grade manufacturing, advanced packaging, precision engineering and industrial automation. Recent developments suggest the relationship is already gaining momentum. As customer demand accelerates across semiconductor and automation markets, JJ Enterprise is evaluating the expansion of up to 100,000 square feet of additional manufacturing capacity across Taiwan and the United States, with NGTF supporting this next phase of growth. The expansion reflects increasing demand for precision manufacturing capabilities and positions the company closer to customers requiring advanced manufacturing, packaging and automation solutions across multiple industries.

Through its Robotics-as-a-Service Provider (“RaaSP”) model, the company is developing scalable automation technologies that address labor shortages, improve operational efficiency, and enhance productivity across commercial environments. Beyond hospitality, TechForce Robotics is expanding into pharmaceutical manufacturing, laboratory automation and industrial applications, markets increasingly adopting intelligent robotics systems to improve consistency, throughput and operational resilience. The company’s support of JJ Enterprise’s manufacturing expansion further reinforces its strategy of building the production capabilities needed to meet growing demand for AI-enabled industrial automation.

Building the intelligent automation infrastructure that enables AI to move to real-world industrial deployment, rather than competing directly in semiconductor design or AI software, positioning the company in a favorable spot. As investment in semiconductor fabrication, advanced packaging and industrial automation continues to accelerate, the company’s expanding relationship with JJ Enterprise and support for additional manufacturing capacity provide tangible evidence that its strategy is evolving from vision to execution.

For more information, visit the company’s website at TechForceRobotics.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• As institutional adoption of digital assets accelerates, demand is shifting toward blockchain infrastructure that prioritizes compliance, security and scalability.
• MindWave Innovations is developing MindChain, an insured Layer 2 blockchain purpose-built to support institutional settlement, tokenization and decentralized finance.
• Built on top of MindChain, the company’s broader ecosystem combines institutional Bitcoin treasury management, AI-driven yield optimization and real-world asset tokenization.

Digital assets have spent more than a decade proving they can survive volatility, skepticism and regulatory uncertainty. The next phase of growth, however, is unlikely to be defined by speculative trading alone. Instead, institutions are increasingly looking for the infrastructure that can support digital assets within the governance, compliance and risk management frameworks expected by boards, regulators and enterprise investors.

That shift is creating demand for blockchain networks designed specifically for institutional participation rather than retail speculation. While first-generation public blockchains demonstrated the technology’s potential, many organizations continue to face challenges surrounding custody, compliance, settlement and operational security. As institutional adoption expands, blockchain infrastructure itself is becoming a critical investment theme.

MindWave Innovations (NYSE American: APUS) is positioning itself within that opportunity through MindChain, its proprietary insured Layer 2 blockchain developed to provide the scalable, secure infrastructure institutions require for digital asset operations. Rather than functioning as another standalone blockchain, MindChain is designed to serve as the foundation for institutional treasury management, decentralized finance, tokenization and enterprise-grade settlement.

The industry’s evolution reflects a broader market trend. Much of Bitcoin’s early value was driven by speculation and rapid price swings, a dynamic that Bloomberg has noted has begun to moderate as institutional participation reshapes the market’s underlying structure. At the same time, corporations and asset managers are increasingly evaluating digital assets as strategic treasury holdings rather than purely speculative investments. That transition places greater emphasis on infrastructure capable of supporting institutional standards for governance, security and operational efficiency.

MindChain was developed with those requirements in mind. The network provides an insured Layer 2 architecture designed to support institutional-scale transactions while improving efficiency, reducing costs and enabling secure settlement across decentralized applications. Its architecture also supports real-world asset (“RWA”) tokenization, allowing traditionally illiquid assets, including private credit, real estate and other alternative investments, to be represented on chain with greater transparency and accessibility.

MindChain also serves as the technological foundation for MindWaveDAO, the company’s broader institutional digital asset ecosystem. Through that platform, corporations can implement board-controlled Bitcoin treasury strategies supported by segregated custody structures and an AI-powered yield engine designed to analyze market conditions and dynamically optimize yield opportunities while managing portfolio risk.

That strategy is already beginning to move beyond concept. In December 2025, Apimeds Pharmaceuticals and MindWave Innovations announced the closing of up to $100 million in PIPE financing tied to establishing an initial Bitcoin treasury position intended to support the platform’s AI-driven yield strategy. In May 2026, the companies announced a settlement resolving outstanding merger-related matters, clearing the path for the merger transactions to proceed and for the financing to advance.

Beyond treasury management, MindChain is intended to support a broader institutional digital asset ecosystem. Its native token, NILA, functions as the network’s gas token while also supporting staking and governance participation, enabling token holders to help guide treasury allocation decisions and ecosystem development.

Rather than focusing solely on cryptocurrency ownership, MindWave Innovations is building infrastructure intended to help institutions participate across multiple segments of the digital asset economy. By combining insured Layer 2 blockchain technology with institutional treasury management, AI-powered yield optimization and real-world asset tokenization, the company is positioning MindChain as the operational backbone for enterprise blockchain adoption.

As digital assets continue moving into the financial mainstream, competitive advantages may increasingly belong to companies building the infrastructure that enables institutional participation rather than those focused exclusively on token performance. Secure settlement, compliant treasury management, scalable blockchain architecture and tokenized financial markets are becoming essential components of the evolving digital economy.

For more information, visit the company’s website at www.MindWaveDAO.com.

NOTE TO INVESTORS: The latest news and updates relating to APUS are available in the company’s newsroom at https://ibn.fm/APUS

• The company launches its 2026 season, designed to move its Skaergaard project into its next phase of development.
• Key critical minerals mined at Skaergaard, including palladium and platinum serve critical industrial functions with few viable substitutes.
• Skaergaard ranks among the world’s largest undeveloped palladium, gold and platinum deposits, and Greenland Mines holds an 80% interest in the licenses covering it.

Argus, a support vessel loaded with drill rigs, just sailed out of Reykjavik, and it is carrying more than equipment. The ship is carrying the opening move of Greenland Mines’ (NASDAQ: GRML) most ambitious field season yet at its Skaergaard project, part of a broader push into the critical minerals the modern economy cannot function without.

“This is the moment the whole season has been building toward,” said Greenland Mines president Dr. Bo Moller Stensgaard. “Argus is loaded, the team is aboard, and we are underway to Skaergaard with everything we need to have a great season — more than 40 experts, three drill rigs drilling, machinery and equipment for bulk-sample blasting and sampling and advanced geophysical survey equipment, aerial drones, and a fully resourced field logistics network, in a program that in our opinion is materially broader than anything that has been run at Skaergaard before.

“Beyond the drilling that will support further upgrading of the resource, we are running an extensive program of environmental, operational, geotechnical and engineering work and investigations this summer that is specifically designed to move Skaergaard into its next phase of development,” he continued. “Everything is lined up. We are ready.”

This move is significant because currently key critical minerals mined at Skaergaard, including palladium and platinum, serve critical industrial functions with few viable substitutes. They are essential to catalytic converters, electronics and hydrogen fuel cells, and the United States government has formally classified platinum as a critical mineral in its own right.

Along with growing importance of these platinum-group metals, another key component of the picture is China’s activity in the space. China designated platinum a strategic critical mineral in late 2025 and began building stockpiles, while roughly 70% of global platinum supply still comes from a single region: South Africa’s Bushveld Complex.

Rare earth elements (“REEs”) are another group of minerals in the today’s spotlight. REEs power the magnets in electric vehicles and wind turbines, the sensors in smartphones and the guidance systems in defense equipment. Yet the supply of these materials remains dangerously concentrated in one country.

China mined around 60% of the world’s rare earths used in magnets in 2024 and controlled roughly 91% of global separation and refining capacity. Beijing has also expanded export licensing requirements on heavy rare earths such as dysprosium, terbium and yttrium, giving it direct leverage over global supply. Governments and manufacturers everywhere are now racing to diversify away from that single point of failure.

Greenland Mines sits at the intersection of both stories. The company operates two divisions, with its mining arm focused on the Skaergaard project in southeast Greenland and, pending the close of a previously announced deal, the Sarfartoq neodymium-praseodymium rare earths project in the country’s southwest. Together, the assets anchor what the company calls its North Atlantic Critical Metals Corridor, a strategy linking Greenland’s resources to allied processing and shipping infrastructure.

Skaergaard itself ranks among the world’s largest undeveloped palladium, gold and platinum deposits, and Greenland Mines holds an 80% interest in the licenses covering it through its subsidiary Major Precious Greenland A/S. The company describes this season as its most comprehensive field season at the site to date, sending its support vessel north from Reykjavik loaded with drill rigs, geophysical equipment and bulk-sampling machinery.

As the 40-plus technical experts, drillers and logistics personnel start the season, the company will have additional specialists rotating in throughout the summer. The program includes resource drilling, bulk sampling, environmental baseline studies and geotechnical work designed to support an upgrade of the Skaergaard mineral resource. It builds on the company’s recently completed S-K 1300 technical report and moves the project toward an initial assessment. The team is also evaluating a potential open-pit mining scenario for near-surface material, alongside the underground concepts already captured in the resource estimate.

Skaergaard’s location carries strategic weight beyond the deposit itself. The site sits roughly 400 kilometers from Iceland along the North Atlantic shipping corridor between Europe and North America, and Greenland Mines holds a right of refusal on the Helguvik industrial complex, a brownfield site with deep-water port access and renewable power. That positioning could support future downstream processing close to Western markets rather than routing materials through China.

As governments push to secure mineral supply chains outside Chinese control, a company advancing both a major platinum group metals deposit and a rare earths project, backed by a defined North Atlantic logistics strategy, is positioned to benefit from that shift. The 2026 field season marks a concrete step toward turning Skaergaard’s geological potential into a producing asset.

For more information, visit www.GreenlandMines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

• Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production yield by 400%.
• The company is advancing commercialization through scalable manufacturing, surgeon training programs, and continued U.S. Phase III clinical progress.
• These developments reinforce Regentis’ strategy of bringing innovative cartilage repair technology from clinical validation to commercial scale, with unit economics that improve as production volumes build.

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC, its innovative cell-free hydrogel implant for focal knee cartilage repair, with a value proposition that extends across the entire healthcare ecosystem. Designed to simplify treatment while improving clinical outcomes, GelrinC offers meaningful benefits for surgeons, patients, and healthcare payers alike. Recent European regulatory approval for a next-generation solvent-free manufacturing process, which boosts production yield by approximately 400%, strengthens the company’s ability to deliver a practical, scalable solution that addresses longstanding limitations in cartilage repair at a much lower production cost.

Unlike complex cell-based therapies or temporary treatment approaches such as microfracture, GelrinC is designed as an off-the-shelf solution. The ready-to-use hydrogel is delivered during a single procedure lasting roughly 10 minutes, cures in situ, and gradually resorbs as the patient’s own cells regenerate durable, hyaline-like cartilage. This combination of procedural simplicity, clinical performance, and favorable economics creates a compelling value proposition for surgeons, patients, and healthcare payers.

The Surgeon Win: Seamless Integration and Procedural Simplicity

Orthopedic surgeons face constant pressure to deliver better outcomes within tight operating room schedules and existing workflows. GelrinC is designed to integrate easily into these orthopedic processes The minimally invasive, single-step procedure takes roughly 10 minutes and requires no cell harvesting, laboratory processing, or staged surgeries.

This streamlined approach fits naturally into the standard surgeon workflows, helping reduce operative complexity compared with many current treatment approaches. With faster ~2-week recovery times (versus 6 weeks or more for some treatments), surgeons can offer patients a more efficient path back to function. Regentis is further supporting adoption through surgeon training programs and European Centers of Excellence, including collaborations with leading institutions such as Humanitas Research Hospital in Milan, Italy.

The Patient Win: Better Outcomes and Faster Return to Life

For patients with focal knee cartilage injuries, durable repair is often more valuable than temporary symptom relief. Clinical data from GelrinC studies show approximately 100% greater improvement in pain and function scores versus microfracture at two years, with MRI evidence of near-native cartilage regeneration and sustained benefits over multiple years.

The shorter recovery period and potential for durable repair translate into quicker returns to work, sports, and daily activities, addressing one of the most frustrating aspects of traditional cartilage treatments.

The Payer Win: Cost-Effectiveness and Value-Based Care

As healthcare systems continue shifting toward value-based care, payers are placing greater emphasis on treatments that improve outcomes while lowering total costs of care. GelrinC aligns well with this shift. As an off-the-shelf product, it avoids the high expenses associated with personalized cell therapies and is expected to the current estimated at $40,000+ cost of cell-based products to one-fourth–~$10,000, while maintaining very strong gross margins. Its shorter 10-minute procedure time, faster patient recovery, and potential to reduce repeat interventions have the potential to improve the overall economic value of treatment for insurers and healthcare systems.

These advantages are especially timely as the U.S. cartilage repair market, estimated at ~$3 billion and encompassing roughly 470,000 annual procedures, continues to grow amid aging populations and rising sports injuries.

Building Commercial Momentum

Regentis is executing on multiple fronts to turn clinical promise into commercial reality. The newly approved solvent-free process lifts production yield by roughly 400% while improving manufacturing efficiency and lowering production costs—important milestones as the company prepares for broader European commercialization.

In the United States, the company continues to advance its pivotal Phase III SAGE trial, which is already over 50% enrolled, under an FDA-approved protocol, and expect to complete enrollment in 2026, while preparing for Premarket Approval (“PMA”) submission. With CE Mark approval already in hand for Europe, these developments position Regentis to potentially establish GelrinC as the first true off-the-shelf regenerative solution in a market that has long lacked practical, durable options.

Why GelrinC Could Become the Standard of Care

By addressing practical challenges related to surgical workflow, clinical durability, and healthcare economics, GelrinC represents more than an incremental advance in cartilage repair. For investors, the case rests on the same economics: off-the-shelf scalability and a lower production cost base, applied to a U.S. cartilage repair market of roughly 470,000 annual procedures and an estimated $3 billion. The company’s continued progress in manufacturing, physician education, and late-stage clinical development demonstrates a deliberate strategy focused on commercial execution as well as clinical innovation.

As current clinical and commercialization milestones continue to build, GelrinC has the potential to reshape the treatment landscape for focal knee cartilage injuries by offering a solution that better aligns the interests of physicians, patients, healthcare systems, and the investors backing them.

This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.

NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT

• A key acquisition brought in the Skaergaard project, a palladium, gold and platinum deposit in southeast Greenland now held through the company’s subsidiary Major Precious Greenland A/S.
• Additional acquisitions, including a rare earths asset, represent the company’s focus on becoming a significant player in the mining space.

A company can rarely reinvent itself overnight, but  Greenland Mines (NASDAQ: GRML), has come close. What started the year as a biotech firm has become a two-division mining company in the span of a few months, and its acquisition activity since then shows no sign of slowing.

Previously known as Klotho Neurosciences Inc., the company traded under the ticker KLTO. In March 2026, however, the company announced two significant changes: a name change to Greenland Mines Ltd and a NASDAQ ticker switch to GRML. In addition, the announcement noted a strategic acquisition that shifted the company’s core focus. The filing was announced through an 8-K with the Securities and Exchange Commission, along with an investor webcast explaining the move to shareholders.

That acquisition brought in the Skaergaard project, a palladium, gold and platinum deposit in southeast Greenland now held through the company’s subsidiary Major Precious Greenland A/S. Since March, the company has continued building momentum. Last month, Greenland reported an updated mineral resource estimate under the SEC’s S-K 1300 standard, raising indicated palladium equivalent metal by 31% to 15.0 million ounces and lifting the indicated grade by 36% to 3.04 grams per tonne.

Earlier, in May, the company signed a definitive agreement to acquire the Sarfartoq neodymium-praseodymium rare earths project from Neo Performance Materials for $35 million, split between $20 million in cash and $15 million in company stock. Sarfartoq’s historic resource includes an estimated 27 million kilograms of neodymium oxide and 8 million kilograms of praseodymium oxide, elements used in the permanent magnets that power electric vehicles and wind turbines. 

Neo Performance Materials is staying involved rather than exiting. The company is retaining an equity stake in Greenland Mines along with offtake rights covering up to 60% of Sarfartoq’s future production once the acquisition closes, effectively lining up a buyer before the project reaches production. Closing remains subject to approval from the Greenland government under the country’s Mineral Activities Act.

The company added a third leg to its strategy in June 2026 through a share exchange agreement with AnorTech Inc., a company trading on the TSX Venture Exchange. Greenland Mines agreed to acquire a 9.9% equity stake in AnorTech for roughly C$5 million, paid in newly issued Greenland Mines shares, with an option to increase its position to as much as 19.9% during the following six months. The deal gives Greenland Mines exposure to sustainable and high-purity alumina production, adding a processing layer above its upstream mining assets.

Notably, the company has not abandoned its biotech roots. Its cell and gene therapy division continues to advance KLTO-202, targeting amyotrophic lateral sclerosis, along with KLTO-101, aimed at Alzheimer’s disease, and additional therapies for Parkinson’s and other age-related disorders. That keeps Greenland Mines as a company with exposure to both natural resources and biotechnology under one publicly traded structure, an unusual combination for a NASDAQ-listed exploration company.

Taken together, the moves since March 2026 show a company moving quickly to build out a broader platform. A name change and ticker switch brought in a flagship precious metals project, a resource upgrade strengthened that project’s regulatory standing, a rare earths acquisition added a second critical mineral exposure with a committed offtake partner and an equity investment added downstream materials optionality. 

For more information, visit www.GreenlandMines.com.

NOTE TO INVESTORS: The latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML

• The company presented its Texatron(TM) Fusion Engine(TM) development program and related scientific research at the American Physical Society Division of Particles and Fields 2026 Meeting held at Fermilab.
• Chief Technology Officer Dr. John E. Brandenburg outlined the company’s Texatron(TM) development efforts alongside his Gravity-Electromagnetic (“GEM”) Unification Theory.
• The company continues to develop the Texatron(TM) Fusion Engine(TM) through its wholly owned subsidiary, Kepler Fusion Technologies, with a focus on modular fusion energy systems.
• American Fusion(TM) believes the theoretical plasma physics concepts presented may complement the ongoing engineering development of the Texatron(TM) platform, although the GEM theory remains subject to continued scientific evaluation.

American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies, has taken another step in advancing the visibility of its fusion energy research, with Chief Technology Officer Dr. John E. Brandenburg presenting the company’s Texatron(TM) Fusion Engine(TM) development program during one of the leading scientific conferences for particle physics.

The presentation took place at the American Physical Society (“APS”) Division of Particles and Fields (“DPF”) 2026 Meeting, hosted at the U.S. Department of Energy’s Fermi National Accelerator Laboratory (“Fermilab”) in Batavia, Illinois. The biennial conference brings together researchers from national laboratories, universities, and research institutions, to discuss developments in particle physics and related fields (https://ibn.fm/lsPyu). 

Alongside an introductory overview of the Texatron(TM) Fusion Engine(TM) program, Dr. Brandenburg presented his Gravity-Electromagnetic (“GEM”) Unification Theory, a theoretical framework that proposes a first-principles mathematical derivation of Newton’s gravitational constant. According to the company, the presentation explored how gravity, electromagnetism, plasma physics, and quantum mechanics, may all be connected within a unified analytical framework.

The GEM theory proposes that Newton’s gravitational constant is not simply an experimentally measured value but emerges from the physical conditions believed to have existed in the early universe. The presentation also discussed the incorporation of quantum mechanics into the model through the fine-structure constant and examined mathematical relationships associated with hydrogen plasma.

While the GEM framework remains a theoretical model requiring continued scientific evaluation, American Fusion(TM) said it believes aspects of the plasma physics discussed could complement future theoretical work supporting the engineering development of the Texatron(TM) Fusion Engine(TM). The company emphasized that its fusion program continues to be driven by experimental validation and ongoing research.

According to the company, the presentation generated substantial audience participation, with attendees posing technical questions regarding the GEM framework and its underlying assumptions. Management characterized the discussion as part of its broader commitment to scientific dialogue and peer engagement as development of the Texatron(TM) platform continues.

“Presenting the Texatron(TM) development program and Dr. Brandenburg’s GEM Unification Theory before one of the world’s premier particle physics communities reflects our commitment to advancing scientific dialogue through rigorous analysis, constructive technical discussion, experimental validation, and peer engagement,” commented Executive Chairman Brent Nelson. “We congratulate Dr. Brandenburg on an outstanding presentation and look forward to continuing our research and development efforts as the Texatron(TM) program advances.”

American Fusion(TM) is developing its fusion technology through its wholly owned subsidiary, Kepler Fusion Technologies. Unlike conventional large-scale fusion concepts requiring centralized facilities, the Texatron(TM) Fusion Engine(TM) is being designed as a modular platform capable of deployment across multiple end markets. Management has previously outlined commercial opportunities that include data centers, industrial facilities, mining operations, defense applications and locations where electric grid capacity is constrained.

The company has also continued expanding its intellectual property portfolio as development progresses. Earlier this year, American Fusion(TM) announced additional U.S. patent filings covering various aspects of the Texatron(TM) platform, reflecting a strategy that combines engineering development with long-term protection of proprietary technologies.

Operationally, the company has continued advancing its testing program during 2026. Previous announcements described regulatory approvals supporting testing activities in Texas and outlined plans to evaluate multiple Texatron(TM) system configurations spanning power outputs from hundreds of kilowatts to multi-megawatt installations. Management has indicated that these efforts are intended to generate engineering data supporting future commercialization.

For more information, visit the company’s website at www.AmericanFusionEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to AMFN are available in the company’s newsroom at https://ibn.fm/AMFN

• The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of the discovery phase with OmniAb.
• OmniAb delivered a portfolio of therapeutic antibody binders, with VERAXA now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation.
• Although VXA-222 is not based on VERAXA’s BiTAC platform, it leverages the company’s proprietary antibody engineering, linker and conjugation technologies and represents one of its more advanced development programs.
• VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads and antibody technologies.
• The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
• VERAXA continues building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.

VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline, announcing that its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program has advanced beyond the discovery phase and into the next stage of development. The milestone reflects continued progress across the company’s therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.

The announcement marks the successful completion of the discovery portion of VERAXA’s collaboration with OmniAb Inc., which began in May 2025 (https://ibn.fm/PBtmc). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own antibody engineering, linker and conjugation technologies. The company will also conduct the in vitro and in vivo validation required before further development.

The VXA-222 program is designed as a bispecific antibody-drug conjugate that uses an “AND-gate” approach to recognize two separate tumor-associated antigens simultaneously. By requiring both targets to be present before delivering its therapeutic payload, the approach is intended to improve tumor selectivity while limiting exposure to healthy tissue.

The collaboration combined complementary capabilities from both companies. OmniAb contributed its antibody discovery platform, including its OmniClic(TM) transgenic chicken technology, which is designed to generate common light-chain antibodies suitable for bispecific therapeutics. Those technologies produced a diverse collection of human antibody candidates optimized through in vivo affinity maturation.

VERAXA now assumes responsibility for transforming those antibody binders into a final therapeutic candidate. The company will apply its proprietary linker technology and conjugation methods to create the finished bispecific antibody-drug conjugate before advancing the program through preclinical evaluation.

Although VXA-222 is not built on VERAXA’s newest BiTAC technology platform, the program illustrates another dimension of the company’s development strategy. Management views VXA-222 as one of its more advanced antibody-drug conjugate programs while continuing to apply the engineering and conjugation expertise developed across its broader technology portfolio.

The company retains exclusive rights to develop and commercialize products arising from the collaboration, while OmniAb is entitled to receive a share of specified future revenues generated by products incorporating the antibodies identified through the partnership.

The latest pipeline progress comes as antibody-drug conjugates continue attracting significant investment across the biotechnology sector. These therapies combine the targeting capability of monoclonal antibodies with highly potent anti-cancer payloads, allowing drugs to be delivered more selectively to tumor cells. Bispecific formats seek to further improve precision by recognizing multiple biological targets simultaneously.

Alongside its pipeline progress, VERAXA recently provided investors with an update on another asset often viewed as equally important for emerging biotechnology companies: its intellectual property portfolio. In a separate announcement issued on July 29, the company disclosed that it had filed its first patent applications covering its newest BiTAC technology platforms, including both BiTAC-TCE and BiTAC-ADC therapeutic programs (https://ibn.fm/Fkn1I).

The new filings extend beyond individual product candidates. They encompass composition-of-matter claims, proprietary payload technologies and innovations supporting the company’s broader antibody engineering platform. Additional patents covering enabling technologies, including click chemistry and conjugation methods, have also completed their opposition periods, further strengthening the company’s intellectual property position.

According to VERAXA, the company now controls a portfolio of more than 50 granted owned or exclusively licensed patents spanning 26 patent families across 14 countries. If the recently submitted applications are ultimately granted, protection for portions of the company’s core technology suite is expected to extend through at least 2047.

The patent activity also highlights the breadth of VERAXA’s research efforts. Rather than concentrating exclusively on individual therapeutic candidates, the company is pursuing innovations across multiple components of antibody therapeutics, including molecular formats, mechanisms of action, linker chemistry, payload technologies and manufacturing approaches.

Much of that work centers on the company’s proprietary BiTAC platform, which is designed to improve tumor selectivity through dual-component molecular architectures. Unlike conventional antibody therapies that rely on a single binding event, BiTAC approaches require simultaneous recognition of two tumor-associated targets before therapeutic activity is activated.

For BiTAC-T cell engagers, this involves two separate antibody constructs that assemble into an active molecule only after binding to the same cancer cell. Within the BiTAC-ADC platform, two antibodies independently deliver inactive components that become therapeutically active only after undergoing a highly specific click-to-release chemical reaction inside targeted tumor cells.

Management believes these approaches may improve safety by reducing activity in healthy tissues while also addressing some manufacturing and stability limitations associated with earlier antibody-drug conjugate technologies.

Beyond BiTAC, VERAXA continues developing a diversified oncology pipeline that includes conventional and bispecific antibody-drug conjugates, engineered antibody formats and additional antibody-based therapeutics. Together with programs such as VXA-222, the expanding patent portfolio reflects a strategy that combines product development with continued investment in the underlying technologies supporting future candidates.

For more information, visit the company’s website at www.Veraxa.com.

NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

• TechForce Robotics deploys AI-powered service robots that automate operational tasks across hospitality, pharmaceutical, laboratory, and industrial environments
• BIM-E, TIM-E, and LIM-E are designed to improve labor efficiency, operational consistency, and scalability rather than serve as novelty attractions
• The company’s expanding robotics ecosystem aligns with growing enterprise demand for automation solutions that deliver measurable business value and return on investment

Not long ago, service robots were largely regarded as attention-grabbing tools, used to create outstanding customer experiences but offering little in terms of operations. Today, that perception is quickly changing. As persistent labor shortages, rising operational costs, and increased demand for efficiency reshape industries globally, businesses are increasingly evaluating robotics based on measuring outcomes, including productivity gains, workforce optimization, cost savings, and return on investment (ibn.fm/KK2Gw).

Nightfood Holdings (OTCQB: NGTF), operating under the name TechForce Robotics, is strategically positioning itself at the nexus of this evolution by developing AI-driven automation solutions that perform practical, repeatable operations tasks across pharmaceutical, hospitality, laboratory, and industrial environments. Rather than building robots designed mainly to entertain, the company is focused on technologies that assist organizations in improving operational performance while reducing dependence on manual labor.

The company’s growing portfolio, including BIM-E, TIM-E and LIM-E, underscore this shift toward customized automation. Rather than serving as customer attractions, these platforms are designed to automate routine operational workflows, improve service consistency and allow employees to focus on higher-value responsibilities.

The rapid expansion of artificial intelligence infrastructure is fueling investment across the broader technology ecosystem, creating ripple effects that extend well beyond data centers and cloud computing. As semiconductor manufacturers, AI hardware providers and enterprise technology companies continue scaling the infrastructure needed to support sophisticated AI models, commercial robotics developers are gaining access to more capable processing power, improved AI functionality and a mature technology stack. These advancements are accelerating the deployment of intelligent robotic systems capable of performing real-world tasks with greater autonomy, reliability and precision.

Through TechForce Robotics, the company is making inroads into laboratory automation, pharmaceutical manufacturing, and industrial applications, sectors where repeatability, precision, and operational efficiency are important. The company’s recently announced partnership with Jiun Jiang (“JJ Enterprise”) to advance AI infrastructure, semiconductor manufacturing automation and pharmaceutical robotics illustrates its commitment to engage in some of today’s fastest-growing technology sectors while broadening its commercial opportunities.

This diversified approach reflects a larger transformation taking place throughout enterprise automation. Rather than deploying isolated robotic solutions to solve individual problems, organizations are investing in integrated AI-enabled platforms capable of improving productivity across multiple operational functions. Companies that can offer adaptable automation technologies spanning several industries may be well positioned as enterprise adoption continues to accelerate.

For investors, the conversation surrounding service robotics is evolving from technological novelty to commercial execution. The key question is no longer whether autonomous systems can perform useful tasks, but whether they can consistently improve operational performance while generating measurable returns. Through TechForce Robotics, Nightfood Holdings is building its strategy around that shift, combining AI-powered automation, an expanding robotics portfolio and targeted acquisitions to position itself alongside the growing enterprise demand for scalable, ROI-driven automation solutions.

For more information, visit the company’s website at TechForceRobotics.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at https://ibn.fm/NGTF

Disseminated on behalf of Powermax Minerals Inc. (CSE: PMAX) (OTCQB: PWMXF) and may include paid advertising.

• Powermax recently commenced its 2026 exploration program at its Cameron REE Project, building on encouraging results from previous exploration and intended to guide the company’s next phase of exploration
• The program is designed to integrate geological mapping, geochemical sampling, and targeted geophysical surveys, to better define and prioritize exploration targets
• The company’s earlier exploration at the property revealed consistent enrichment of both light and heavy rare earth elements across multiple lithological units
• The three-week field program has been designed to follow up encouraging results from previous stream sediment, soil, and rock geochemical surveys

Powermax Minerals (CSE: PMAX) (OTCQB: PWMXF), a Canadian mineral exploration company, recently announced that it had commenced its 2026 exploration program at its 100%-owned Cameron Rare Earth Element (“REE”) project located in the Kamloops Mining Division of British Columbia. The three-week program is a follow-up to the encouraging results from previous stream sediment, soil, and rock geochemical surveys, which were conducted as part of the company’s Phase 2 exploration program at the property (https://ibn.fm/We2oM).

The 2026 exploration program will be conducted using road-supported access and limited, supplementary helicopter support where necessary. It will include detailed geological mapping and prospecting, selective rock sampling, infill soil sampling, additional stream sediment sampling, ground radiometric sampling, and the integration of datasets into a comprehensive target ranking model to support future trenching and first-pass drill planning.

This program aims to refine the location and continuity of previously identified REE target corridors; better define potential bedrock sources responsible for anomalous stream sediments and soil geochemistry; improve geological understanding of pegmatite-hosted REE mineralization; and integrate geological, geochemical, and radiometric information to prioritize targets for follow-up trenching and drill testing.

“We are pleased to commence this important 2026 exploration program at the Cameron REE Project. Building on encouraging results from previous exploration, this program has been designed to integrate geological mapping, geochemical sampling and targeted geophysical surveys to better define and prioritize exploration targets. We look forward to completing the program and using the results to guide the next phase of exploration,” commented Paul Gorman, CEO of Powermax Minerals.

The Cameron REE Property is a 2,984-hectare project located strategically within a tier-1 mining jurisdiction. It boasts world-class infrastructure, with Canada’s Highway 23 traversing the property and connecting to the Trans-Canada Highway 1 30 kilometers to the north. The project contains three contiguous mining claims whose historic exploration shows potential REE, niobium, and other mineralization. 

Phase 1 and Phase 2 Exploration Programs

Powermax Minerals completed its Phase 1 exploration, which confirmed the presence of light rare earth element (“LREE”) and heavy rare earth element (“HREE”) mineralization across the property. The Phase 1 results showed total REE (“TREE”) values ranging from 17 ppm to 1,943 ppm, while the heavy mineral concentrates samples had TREE values ranging from 365 ppm to 7,561 ppm. The results also showed consistent enrichment of both LREEs and HREEs across multiple lithological units, with LREEs being more abundant than HREEs. 

These results encouraged the company to commence its Phase 2 exploration program in October 2025. The Phase 2 program’s objectives included geological mapping and systematic rock sampling, additional stream sediment and soil geochemical surveys, and the integration of geological, geochemical, and geophysical datasets in a GIS platform to refine and prioritize drill targets (https://ibn.fm/TAUzx).

The soil geochemical sampling program returned total rare earth oxide (“TREO”) values ranging between approximately 135 ppm and 2,840 ppm, while the surface rock samples returned TREO values ranging from 36 ppm to 740 ppm (https://ibn.fm/N9mva). Moreover, the results from the stream sediment sampling showed elevated light rare earth oxides (“LREOs”), heavy rare earth oxides (“HREOs”) and TREO (https://ibn.fm/n57E5). By completing these programs and reporting the results, the company is taking important steps to systematically advance the project, which could add significant value for its shareholders.

Exploration Target Cautionary Statement

The exploration targets discussed are conceptual, and there is currently not enough data to confirm a mineral resource. Further exploration may not yield successful results.

For more information, visit the company’s website at www.PowermaxMinerals.com.

NOTE TO INVESTORS: The latest news and updates relating to PWMXF are available in the company’s newsroom at https://ibn.fm/PWMXF